Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil shows promise for Tough-to-Treat asthma

NCT ID NCT05613803

Disease control Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking high-dose fish oil (n-3 PUFA) for 6 months can improve asthma control in adults with a specific type of asthma called N-ERD, which is triggered by aspirin or NSAIDs. The 18 participants had poorly controlled asthma despite standard treatment. The goal was to see if the supplement could reduce inflammation and improve symptoms, offering a potential add-on therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Started

Oct 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. aged ≥18 years. N-ERD does not occur at birth and it rarely occurs in children. 2. physician labelled diagnosis of asthma. 3. history of N-ERD according EAACI guidelines(9) with evidence of one of 1) Clinical diagnosis as evidence by i. A reliable history of aspirin or NSAID induced respiratory reaction as evidenced by more than one reaction, reactions to two or more different NSAIDs or the last reaction occurring within the last 5 years plus ii. Recurrent nasal polyposis, anosmia, moderate to severe asthma, intolerance to alcohol and/or blood eosinophilia 2) Positive nasal or bronchial aspirin challenge(43) 4. ACQ of more than 1.5 as this indicates poor control. This is required to ensure there is a clinical need or a requirement to alter medication. 5. stable disease, as evidenced by a lack of change in asthma therapy within the last 6 weeks. Exclusion Criteria: 1. significant cardiac disease, respiratory disease or other cause for breathlessness other than asthma 2. severe or uncontrolled co-morbid disease (other than nasal polyps) which is likely to affect the outcome of the study 3. having had an upper or lower respiratory tract infection requiring antibiotics within four weeks of randomisation 4. receiving aspirin desensitisation therapy or biologic agents 5. receiving n-3 fatty acid oral supplements 6. current smoker or more than 15 pack-year smoking history 7. consumption of more than 21 units of alcohol per week as alcohol-induced respiratory symptoms are more common in N-ERD. 8. patients unable to give written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspirin-induced respiratory disease asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    Norwich, Norfolk, NR4 7UY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.